First in Human Pilot Study to Assess the Safety and Efficacy of Dendritic Cells Loaded With Frameshift Derived Neopeptides for the Prevention of Cancer in of Lynch Syndrome Carriers

Phase 1 Recruiting 20 enrolled Fundacion Clinic per a la Recerca Biomédica

NaSingle-groupOpen-labelPrevention

Summary

Tha aim of this clinical trial is to evaluate safety and tolerability of autologous peripheral blood differentiated and matured adult dendritic cells. Immunogenicity of the prduct(DC-DELAY) will be evaluated also.

Timeline

Start: 2025-09-04
Primary completion: 2028-09-20
Completion: 2028-09-20

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	DC-DELAY	Cell therapy	—	Intravitreal

First in Human Pilot Study to Assess the Safety and Efficacy of Dendritic Cells Loaded With Frameshift Derived Neopeptides for the Prevention of Cancer in of Lynch Syndrome Carriers

Summary

Timeline

Drugs

Indications